Navigation Links
Amarillo Biosciences Announces Plan to Open Asia Operations Center in Taipei, Taiwan

AMARILLO, Texas, June 26, 2012 /PRNewswire/ -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced a plan to open its Asia Operations Center in Taipei, Taiwan. This new center will enable ABI to increase its presence in Taiwan in order to access growing markets in mainland China and in other Asian countries.

Dr. Stephen Chen, ABI's Chairman & CEO, said, "This new Asia Operations Center will explore new business opportunities in Asia, seek licensing opportunities, and evaluate investment proposals. Interviews for its new staff will begin immediately in an effort to have the center fully operational in the third quarter of this year." 

"The new staff will include a general manager, scientific and business administrators, and numerous project managers," Dr. Chen added.

The mission of the Asia Operations Center is fourfold.  First, the Asia Center will introduce novel healthcare products and technologies from the U.S. into the Asian markets. Second, the Asia Center will be responsible for identifying and developing new strategic partners in the region.  Third, the Center will be poised to seek out new sources of financing when the need arises.  Fourth, the Asia Center will identify new healthcare products and technologies that can be brought into the U.S. from the Asian regions to be distributed by ABI.About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with Hayashibara Company, Ltd., a wholly-owned subsidiary of the Nagase Group, which also holds 4% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures about Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2011.  Investor Relations: Philippe Niemetz

Stephen T. Chen, Ph.D.PAN Consultants, Ltd.

Chairman and CEOemail:

e-mail: Tel: 212-344-6464

Tel: 626-407-2570Fax: 212-618-1276 Bernard Cohen Vice President & CFO email: Tel: 806-376-1741 ext. 16 Fax: 806-376-9301

SOURCE Amarillo Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
2. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
3. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
4. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
5. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
6. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
7. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
8. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Ambit Biosciences to Present at Two Upcoming Investor Conferences
Post Your Comments:
(Date:12/1/2015)... Texas (PRWEB) , ... December ... ... , a leading relationship marketing company specializing in scientifically backed, age-defying products, ... January 2016 issue, which highlights the exponential success and unrivaled opportunities that ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... global meeting this month and Dr. J. Kyle Mathews will join ... includes the new single site hysterectomy. , An experienced urogynecologist, founder of Plano ...
(Date:11/30/2015)... ... ... Global Stem Cells Group announced that its scientific team is in the ... cells. The announcement starts a new phase toward launching the simple, quick system for ... lipoaspirate obtained from liposuction of excess adipose tissue. , Lipoaspirate, contains a large ...
(Date:11/30/2015)... MONTREAL , Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... that it has joined the American Business Act on Climate ... economy that are standing with the Obama Administration to demonstrate ... for a strong outcome to the COP21 Paris ... . --> Sarnia, Canada . ...
Breaking Biology Technology:
(Date:11/17/2015)... Nov. 17, 2015  Vigilant Solutions announces today that ... Board of Directors. --> ... retiring from the partnership at TPG Capital, one of ... over $140 Billion in revenue.  He founded and led ... the TPG companies, from 1997 to 2013.  In his ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
Breaking Biology News(10 mins):